http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#Head http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#assertion http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#provenance http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#pubinfo http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#assertion http://purl.obolibrary.org/obo/DOID_9538 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_9538 http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00480 http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#association http://www.w3.org/2000/01/rdf-schema#label revlimid is a thalidomide analogue indicated for the treatment of patients with multiple myeloma mm in combination with dexamethasone 1 1 mm as maintenance following autologous hematopoietic stem cell transplantation auto hsct 1 1 transfusion dependent anemia due to low or intermediate 1 risk myelodysplastic syndromes mds associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities 1 2 mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomib 1 3 limitations of use revlimid is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia cll outside of controlled clinical trials 1 4 revlimid in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma mm revlimid is indicated as maintenance therapy in patients with mm following autologous hematopoietic stem cell transplantation auto hsct revlimid is indicated for the treatment of patients with transfusion dependent anemia due to low or intermediate 1 risk myelodysplastic syndromes mds associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities revlimid is indicated for the treatment of patients with mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomib revlimid is not indicated and is not recommended for the treatment of patients with cll outside of controlled clinical trials see warnings and precautions 5 5 http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00480 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#provenance http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#pubinfo http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#sig http://purl.org/nanopub/x/hasSignature AKGzVXAkh1pljS2u+vEiN8pgGcSLUZsSTzkVh9ZaVQyhswnkR9G05TcE9HlNVuaBub8A+EzG6zfEEQWdjRSweJNBrObYSCW2+y40KXhivkGBpIyJQt2i2ULAG6irGy9zVVp4gH0U70PKLqxbKvTBwb93BxlHt66U7NF8JaPJXaU= http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA http://purl.org/dc/terms/created 2021-07-03T12:50:52.635+02:00 http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs